Clinical trial NCT00638157: Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
Official title: A Phase 4 Multicenter, Randomized, Double Blind Study to Describe the Efficacy and Safety of Cubicin® (Daptomycin for Injection) With and Without Initial Gentamicin Combination Therapy in the Treatment of S. Aureus Infective Endocarditis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Infective Endocarditis
Keywords: Gram-positive bacterial infections
Staph Aureus
endocarditis
bacteremia
methicillin-resistant Staphylococcus aureus (MRSA)
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Sponsor class: INDUSTRY
First posted: 2008-03-18
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE

Detailed description: Patients will be randomized to either of the following two treatment arms:

* Arm 1: daptomycin
* Arm 2: daptomycin with initial i.v. gentamicin

Patients who meet all the inclusion criteria and exhibit none of the exclusion criteria may be enrolled. Intravenous drug user (IVDU) patients may be randomized and study drug begun on the basis of two separate peripheral blood cultures positive for S. aureus obtained within 96 hours prior to the first dose of study drug.

The recommended minimum duration of treatment for daptomycin will be 28 days. The duration of treatment for gentamicin will be 3 days.

During study treatment, regular assessments (including weekly safety laboratory testing including CPK) will be performed. An End-of-Therapy (EOT) evaluation will be performed on the day of or 1-2 days after completion of daptomycin study drug or upon early termination (ET). All patients will have a post-therapy visit for Test of Cure (TOC)/Safety performed 21-28 days following the last dose of daptomycin study drug.

Eligibility criteria: Inclusion Criteria:

1. Written informed consent has been obtained;
2. Male or female ≥18 years of age;
3. IVDU (as confirmed by history of drug abuse within the past 3 months or recent needle track marks);
4. Definite or possible IE according to the modified Duke Criteria (see Appendix A); \[17 \];
5. Two blood cultures positive for S. aureus obtained within 96 hours prior to first dose of study medication acquired by fresh venipuncture using aseptic technique and analyzed at the local laboratory (see Appendix B).

Exclusion Criteria:

1. Intravascular foreign material in place at the time that the positive blood culture was drawn (e.g., intracardiac pacemaker wires, percutaneous or implanted venous catheters, vascular grafts), (exception: vascular stents that have been in place for \>6 months or permanent pacemaker wires attached via epicardial leads are allowed);
2. High likelihood of LIE as indicated by:

   1. Prior diagnosis of predisposing left-sided valvular pathology (e.g., rheumatic heart disease, bicuspid aortic valve); or
   2. Findings on screening examination of left-sided valvular pathology (e.g., diastolic murmur of aortic insufficiency); or
   3. Findings on screening examination of major systemic emboli to visceral organs (e.g. cerebral or splenic infarct). Patients may be included if their only findings are consistent with microvascular phenomena due to immune complexes (e.g., splinter hemorrhages, conjunctival petechiae, Roth's spots, Osler's nodes, Janeway's lesions, microhematuria).

   Note: Any patient enrolled in the study that is subsequently found to have LIE may be continued in the trial if determined to be clinically improving by the Investigator.
3. Prosthetic heart valve;
4. Baseline Creatinine clearance of \<30 mL/min (as calculated by the Cockcroft-Gault equation using actual body weight);
5. Baseline CPK value 5 X upper limit of normal (ULN) in conjunction with symptoms of myalgia or baseline CPK value 10 X ULN without symptoms;
6. Alanine aminotransferase (ALT) \>5 X ULN;
7. Aspartate aminotransferase (AST) \>5 X ULN;
8. Moribund clinical condition (i.e. high likelihood of death within 3 days after randomization);
9. Shock or hypotension (supine systolic blood pressure \<80 mm Hg) or oliguria (urine output \<20 mL/h) unresponsive to fluids or pressors within 4 hours;
10. Known pneumonia or osteomyelitis;
11. Polymicrobial infection or bacteremia due to a pathogen other than S. aureus;
12. Neutropenia (absolute neutrophil count \< 0.5 X 103/μL) and/or lymphopenia (CD4 lymphocytes \<0.2X 103/μL);
13. Anticipated to require non-study antibiotics that may be potentially effective against S. aureus;
14. Prior gentamicin therapy \> 1 day;
15. Documented history of significant allergy or intolerance to any of the study medications;
16. Unlikely to comply with study procedures;
17. Pregnant or nursing. All females with childbearing potential will have a pregnancy test performed at the local laboratory.
18. Female of childbearing potential and not willing to practice barrier methods of birth control (e.g., condoms or diaphragms together with spermicidal foam or gel) during treatment and for at least 28 days after treatment with study medication

Primary outcomes:
measure: Summary of Clinically Significant Increases in Serum Creatinine by Visit
timeFrame: Baseline, EOT Visit, TOC
Secondary outcomes:
measure: Summary of the Investigator's Assessment of Clinical Response at the TOC Visit
timeFrame: TOC Visit
Other outcomes:
Locations:
city: Denver
country: United States
facility: Denver Health Medical Center
state: Colorado
city: Detroit
country: United States
facility: Wayne State University
state: Michigan
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Philadelphia
country: United States
facility: Temple University School of Medicine
state: Pennsylvania
Study officials:
affiliation: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
name: Paula Bokesch, M.D.
role: STUDY_DIRECTOR
References: